

## Shionogi & Co., Ltd. releases AMR Position Paper

Shionogi & Co., Ltd. (Shionogi) announces that the company has prepared and released its “Shionogi AMR Position Paper.”

Antimicrobial resistance (AMR) is a global threat, with some reports saying that it could cause up to 10 million fatalities annually by 2050 unless we take measures against it. Regarding this social challenge against AMR, this AMR Position Paper details the point of view and efforts of Shionogi, which has been tackling the issue of drug-resistant bacteria for many years with a focus on infections.

Shionogi considers it necessary to take the following actions against AMR:

1. Create a predictable and sustainable market for AMR products through economic incentives, such as pull incentives and new value assessments for reimbursement
2. Harmonize global regulations for development and approval of new antibiotics
3. Establish clinical trial networks to help execute clinical studies more efficiently
4. Ensure appropriate use of antibiotics through regulation of animal use, stewardship, and timely surveillance of resistance epidemiology
5. Make effective medicines available for patients in need directly or via alliance partners
6. Reduce environmental impact from manufacture of antibiotics

All employees of Shionogi are proud of the company’s declaration to continue research and development activities for the new treatment of infections and will continue to make best efforts so that both patients and society benefit from effective therapeutic drugs for the treatment of AMR.

The “Shionogi AMR Position Paper” includes details of the background information and Shionogi’s role and strategies.

<Websites>

English: <http://www.shionogi.co.jp/en/company/csr/activities/amr.html>

Japanese: <http://www.shionogi.co.jp/company/csr/act/amr.html>